Evidence map›Paper›PMID 33213205›Full record

ReviewExpert review of pharmacoeconomics & outcomes research2021

Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews.

Vakaramoko Diaby, Reem D Almutairi, Aram Babcock, Richard K Moussa, Askal Ali

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of pharmacoeconomics & outcomes research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Vakaramoko DiabyDepartment of Pharmaceutical Outcomes and Policy (POP), College of Pharmacy, HPNP 3317, University of Florida, Gainesville, FL, USA.ORCID https://orcid.org/0000-0002-6251-0773
Reem D AlmutairiDepartment of Pharmaceutical Business and Administration Sciences, MCPHS University, Boston, MA, USA.ORCID https://orcid.org/0000-0002-4391-5345
Aram BabcockDepartment of Pharmaceutical Outcomes and Policy (POP), College of Pharmacy, HPNP 3317, University of Florida, Gainesville, FL, USA.
Richard K MoussaUniversité De Cergy-Pontoise, France and Ecole Nationale Supérieure De Statistiques Et d'Economie Appliquée (ENSEA), Côte d'Ivoire.ORCID https://orcid.org/0000-0003-0046-1053
Askal AliCollege of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA.ORCID https://orcid.org/0000-0002-0535-6300
University of Florida · USÉcole Nationale Supérieure de Statistique et d'Économie Appliquée · CIFlorida Agricultural and Mechanical University · USMassachusetts College of Pharmacy and Health Sciences · US

Funding

Research Project-3: Effectiveness of an eHealth intervention for uptake of cervical cancer screening in Hispanic womenU54MD007582 · NIMHD · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI Seth Y Ablordeppey · 2019 to 2026
$28.1M
NIMHD NIH HHS U54 MD007582
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Molecular Targeted TherapyAntineoplastic AgentsBreast NeoplasmsCost-Benefit AnalysisErb-b2 Receptor Tyrosine KinasesFemaleHumansNeoplasm MetastasisSurvival RateSystematic Reviews as TopicAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBreast cancercost-effectivenessher2-positive receptorsmetastasessystematic review

Identifiers

PMID33213205
PMCPMC8765058
OpenAlexW3104747470

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.